Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke

Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin Trial. A Placebo-Controlled Trial Of High-Dose Atorvastatin In Patients With Cerebral Small Vessel Disease.

The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.

Inclusion Criteria:

• clinically defined lacunar syndrome 3 months before inclusion
• small deep infarct on diffusion MRI (Diffusion Weighted Imaging)
• no atherothrombotic, cardio-embolic, or other rarer cause.

Exclusion Criteria:

• patients with past coronary event
• contra-indication for assessment of vasomotor reactivity
• patients being on statin therapy at the time of brain infarction
• contra-indication for statin therapy
• patient still under statin therapy